News

Oxycyte will be manufactured at Hospira’s Clayton, North Carolina, facility which specializes in emulsion technology. Hospira will formulate, fill, finish and label Oxycyte to meet clinical good manufacturing

According to Cerus, the Intercept blood system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of known and emerging pathogens, including viruses,

The Phase Ib open-label, dose-escalating study will enroll up to 30 patients diagnosed with IgA nephropathy at clinical sites in Canada. The trial design utilizes a continuous reassessment

The collaboration will deploy Ensemble’s proprietary drug discovery platforms and Ensemblin collections to discover and advance drug candidates. Bristol-Myers Squibb will have the right to develop and commercialize

The State Intellectual Property Office of the People’s Republic of China has issued a new Chinese patent which provides composition of matter protection for Rib-X’s novel oxazolidinone antibiotic,

The sale is believed to have achieved Clinical Data’s goal to monetize non-core assets and focus resources on advancing its two late-stage targeted therapeutic programs, each of which

Cell Therapeutics (CTI) expects to complete the submission this quarter and will request priority review which if granted could lead to an approval decision from the FDA in

In this agreement, Syntopix will make available the company’s library of compounds for evaluation of their application in a number of areas as candidates for development into commercial

US-based pharmaceutical company Pharmacyclics has initiated treatment in a Phase I dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton’s